Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study (Q46501449)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 October 2012

Language	Label	Description	Also known as
English	Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study	scientific article published on 12 October 2012

Statements

scholarly article

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study (English)

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

chronic hepatitis B

1 reference

based on heuristic

inferred from title

object named as

Tetsuya Hosaka

1

0 references

Hiromitsu Kumada

13

object named as

Hiromitsu Kumada

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

Fumitaka Suzuki

2

object named as

Fumitaka Suzuki

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

11

object named as

Kenji Ikeda

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

Masahiro Kobayashi

3

object named as

Masahiro Kobayashi

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

Yoshiyuki Suzuki

8

object named as

Yoshiyuki Suzuki

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

7

object named as

Norio Akuta

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

10

object named as

Yasuji Arase

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

6

object named as

Hitomi Sezaki

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

9

object named as

Satoshi Saitoh

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

Yusuke Kawamura

5

object named as

Yusuke Kawamura

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

Mariko Kobayashi

12

object named as

Mariko Kobayashi

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

author name string

Yuya Seko

4

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

publication date

12 October 2012

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

Journal of Gastroenterology

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

48

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

930-941

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

8

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

Hepatitis B virus infection--natural history and clinical consequences

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Is response to antiviral treatment influenced by hepatitis B virus genotype?

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0688-7

21 January 2018

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

1 reference

https://pubmed.ncbi.nlm.nih.gov/23065021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23065021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/23065021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23065021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/23065021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/23065021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/23065021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23065021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-012-0688-7

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23065021

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46501449&oldid=2114482124"